Higher doses or increased dosing frequency of Clarinex-D 24 Hour Extended Release Tablets have not demonstrated increased effectiveness. Changes in Desloratadine and 3-hydroxydesloratadine Pharmacokinetics in Healthy Male and Female Subjects. In another study, following administration of single oral doses of desloratadine 5 mg, C max and AUC values increased in a dose-proportional manner between 5 and 20 mg. Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Pseudoephedrine sulfate is an orally active sympathomimetic amine and exerts a decongestant action on the nasal mucosa. Clarinex-D 24 Hour Extended Release Tablets should be administered when the antihistaminic properties of desloratadine and the nasal decongestant properties clarinex extended release pseudoephedrine are desired [see Clinical Pharmacology 12 ]. The mean plasma elimination half-life of desloratadine was The median exposure AUC to desloratadine in the poor metabolizers was approximately 6-fold greater than in the clarinex extended release who are not poor metabolizers. For 3-hydroxydesloratadine, the mean C.
Nasal Allergy Relief Products Slideshow Pictures. Clarinex-D 24 Hour Extended Release Tablets should generally be avoided in patients with renal impairment [see Clinical Pharmacology 12 ]. Patients should be instructed to use CLARINEX-D 24 HOUR Extended Release Tablets as directed. CLARINEX-D 24 HOUR Extended Release Tablets should generally be avoided in patients with hepatic insufficiency. Say Goodbye to Allergy Misery in Spring. This leaflet does not take the place of talking to your doctor about your medical condition or treatment. It has an empirical formula: C. In addition to these events, the following spontaneous adverse events have been reported during the marketing of desloratadine as a single ingredient product: headache, somnolence, dizziness, tachycardia, and rarely hypersensitivity reactions such as rash, edema, dyspnea, and anaphylaxis , movement disorders including dystonia, tics, and extrapyramidal symptoms , seizures, and elevated liver enzymes including bilirubin and very rarely, hepatitis. There was no difference in the prevalence of poor metabolizers across age groups. Desloratadine and 3-hydroxydesloratadine are not eliminated by hemodialysis.
The elimination half-life is approximately 3 to 6 or 9 to 16 hours when the urinary pH is 5 or 8, respectively. Higher doses or increased dosing frequency of Clarinex-D 24 Hour Extended Release Tablets have not demonstrated increased effectiveness. Stop using this medication and call your doctor at once if you have a serious side effect such as: fast, pounding, or uneven heartbeat; confusion, hallucinations, unusual thoughts or behavior; severe dizziness, anxiety, restless feeling, or nervousness; dangerously high blood pressure severe headache, blurred vision, buzzing in your In subjects with severe renal impairment or who were hemodialysis dependent, C max and AUC values increased by approximately 1. The chemical name is 8-chloro-6,dihydro 4-piperdinylidene -5 H -benzo[5,6]cyclohepta[1,2- b ]pyridine and has the following structure:. In the above single-dose pharmacokinetic study, the mean time to maximum plasma concentrations T max for desloratadine occurred at approximately 6—7 hours postdose and mean peak plasma concentrations C max and area under the concentration-time curve AUC tf of approximately 1. Each tablet contains 5 mg desloratadine in the tablet coating for immediate release and mg pseudoephedrine sulfate USP in an extended release core. If such a reaction occurs, therapy with Clarinex-D 24 Hour Extended Release Tablets should be stopped and alternative treatment should be considered [see Adverse Reactions 6. The empirical formula for pseudo-ephedrine sulfate is C.